Intérêt de l'anti-interleukine-5 dans le traitement du syndrome hyperéosinophile et des maladies allergiques

The hypereosinophilic syndrome, and asthma and other allergic diseases are characterized by a proliferation and/or activation of polynuclear eosinophils, the production, maturation and activation of which are mediated by interleukin-5 (IL-%). In recent years, several preparations having anti-IL5 activity, aimed at regulating the activity of eosinophils, have been developed and evaluated. Still, there have been few clinical studies. Two molecules, STI-571 and SB-240563 have been found to have interesting results in phase I/II studies in the hypereosinophilic syndrome, with amelioration of clinical and biological parameters. One phase III study of SB-240563 in this condition is presently underway. In asthma, in spite of a significant reduction of infiltration of eosinophils in the blood and tissues, no molecule has as yet shown clinical benefit.